Aeterna Zentaris Inc

* Aeterna Zentaris and Orient Europharma Co Ltd signexclusive license agreement for Zoptrex in Taiwan and SoutheastAsia

* Co will be entitled to receive non-refundable upfrontpayment for license to Cyntec of co's intellectual propertyrelated to Zoptrex

* Company expects to complete Phase 3 clinical trial in Q3of 2016 for Zoptrex

* Cyntec agreed to make additional payments to co uponachieving certain pre-established regulatory and commercialmilestones

* Company will receive royalties on future net sales ofZoptrex in Taiwan, 9 countries in Southeast AsiaSource text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)